EUVIMEDEUVIMED entdecken
Crossref

A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity

S Heinze, C Dorneburg, JP W Heidbuechel, C E Engeland, C Beltinger

Klinische Pädiatrie · 01.05.2024 · 236 (03) · 207

DOI: 10.1055/s-0044-1786587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von S Heinze und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CD19xCD3 bispecific T-cell engager (BiTE) blinatumomab is effective against BCP-ALL by engaging CD3+ T cells with CD19+ leukemic blasts. However, its systemic administration can elicit severe side effects and despite additional HSCT long-term overall survival in relapsed/refractory ALL is poor. This new oncolytic measles virus (MV) expressing the anti-CD19 BiTE (MV-Blina) decreases BCP-ALL cell numbers concomitant with increased expression of blinatumomab (secBlina) in infected cells. Purified secBlina from supernatants of infected cells specifically binds to target cells, activates T cells and effectively kills REH BCP-ALL cells in the presence of PBMCs. The elucidation of therapeutic effectiveness of MV-Blina in mice bearing patient-derived xenografts is under investigation. In addition, we addressed the toxicity of MV-Blina in human neuronal cells in vitro. Here, MV-Blina showed a pronounced oncolytic effect on the neuroblastoma cell line SY5Y whereas healthy iPSC-derived human neurons were less affected. The assessment of toxicity in a recombinant susceptible mouse model is ongoing. Altogether, MV-Blina may be a new therapeutic approach in ALL. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Heinze, S., Dorneburg, C., Heidbuechel, J. W., Engeland, C. E., & Beltinger, C. (2024). A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity. Klinische Pädiatrie, 236(03), 207. https://doi.org/10.1055/s-0044-1786587

Vancouver

Heinze S, Dorneburg C, Heidbuechel JW, Engeland CE, Beltinger C. A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity. Klinische Pädiatrie. 2024;236(03):207. doi:10.1055/s-0044-1786587

BibTeX
@article{Heinze2024,
  author = {Heinze, S and Dorneburg, C and Heidbuechel, JP W and Engeland, C E and Beltinger, C},
  title = {A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity},
  journal = {Klinische Pädiatrie},
  year = {2024},
  volume = {236},
  number = {03},
  pages = {207},
  doi = {10.1055/s-0044-1786587}
}
Kostenlos starten →